» Articles » PMID: 28599435

Expression of Regulatory Factor X1 Can Predict the Prognosis of Breast Cancer

Abstract

Breast cancer (BC) is the most common malignancy among women. Identifying novel biomarkers to predict prognosis accurately is important in managing this disease. The regulatory factor X1 () gene is a member of the regulatory factor X gene family. Its protein reportedly downregulates the proto-oncogene , but its role in BC has been unclear. In this study, expression and methylation status of were determined in BC cell lines. We then evaluated mRNA expression levels with regard to clinicopathological factors including postoperative prognosis in 167 patients with BC. Expression of was heterogeneous among cell lines, and we found no DNA methylation at the promoter region. Patients were categorized into groups with high or low expression, based on ratio of mRNA expression in BC and adjacent non-cancerous tissues. The high group was significantly associated with low T factor (P=0.028), earlier disease stage (P=0.015), positive expression of estrogen receptor (P=0.005) and progesterone receptor (P=0.011), negative expression of human epidermal growth factor receptor 2 (P=0.001). The high group experienced more favorable disease-free survival (P=0.007) and overall survival (P=0.013). In multivariate analysis, expression was an independent prognostic factor for disease-free survival. Our findings indicate that may serve as a prognostic marker for BC.

Citing Articles

Adenylate cyclase 9 expression level is associated with hormone receptor-positive breast cancer and predicts patient prognosis.

Sugino K, Shibata M, Adachi Y, Soeda I, Ichikawa T, Inaishi T Nagoya J Med Sci. 2025; 86(4):665-682.

PMID: 39780930 PMC: 11704764. DOI: 10.18999/nagjms.86.4.665.


Metabolic Switch in Endocrine Resistant Estrogen Receptor Positive Breast Cancer.

Brechbuhl H, Han A, Paul K, Nemkov T, Ramachandran S, Ward A bioRxiv. 2025; .

PMID: 39763830 PMC: 11703175. DOI: 10.1101/2024.12.28.630631.


Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer.

Ichikawa T, Shibata M, Inaishi T, Soeda I, Kanda M, Hayashi M Curr Oncol. 2021; 28(5):4080-4092.

PMID: 34677264 PMC: 8535095. DOI: 10.3390/curroncol28050346.


RFX1: a promising therapeutic arsenal against cancer.

Issac J, Raveendran P, Das A Cancer Cell Int. 2021; 21(1):253.

PMID: 33964962 PMC: 8106159. DOI: 10.1186/s12935-021-01952-6.


MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer.

Watanabe M, Shibata M, Inaishi T, Ichikawa T, Soeda I, Miyajima N Oncol Lett. 2020; 20(5):198.

PMID: 32963604 PMC: 7491119. DOI: 10.3892/ol.2020.12059.


References
1.
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

2.
Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

3.
Spiegel I, Shaul Y . The dimerization/repression domain of RFX1 is related to a conserved region of its yeast homologues Crt1 and Sak1: a new function for an ancient motif. J Mol Biol. 1999; 294(1):121-37. DOI: 10.1006/jmbi.1999.3245. View

4.
Rauscher G, Kresovich J, Poulin M, Yan L, Macias V, Mahmoud A . Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer. 2015; 15:816. PMC: 4625569. DOI: 10.1186/s12885-015-1777-9. View

5.
Watts J, Zhang C, Klein-Szanto A, Kormish J, Fu J, Zhang M . Study of FoxA pioneer factor at silent genes reveals Rfx-repressed enhancer at Cdx2 and a potential indicator of esophageal adenocarcinoma development. PLoS Genet. 2011; 7(9):e1002277. PMC: 3174211. DOI: 10.1371/journal.pgen.1002277. View